Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
110 participants
OBSERVATIONAL
2017-03-02
2017-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
New Diabetes Mellitus and Pre-Diabetes With First-time Diagnosed Coronary Artery Disease
NCT05208424
Coronary Artery Disease Severity in Newly Diagnosed Dysglycemia
NCT05210972
Mechanisms of Endothelial Dysfunction in Type 2 Diabetes
NCT02311075
Serum Magnesium Level in Type 2 Diabetes Mellitus
NCT06059833
Correlation Between Micro Vascular Complications and Severity of Coronary Artery Disease in Type 2 DM
NCT04975828
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
Fifty-five coronary artery disease patients without type 2 DM
serum endostatin level
An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.
Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA
Group II
Fifty-five coronary artery disease patients with type 2 DM
serum endostatin level
An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.
Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
serum endostatin level
An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.
Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 2 diabetic patients with the onset of type 2 diabetes occurred at age 30 years or older with no history of ketoacidosis for group II subjects.
Exclusion Criteria
50 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zagazig University
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hazem Mohamed Elashmawy
Professor of Internal Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hazem M Elashmawy, MD. Msc
Role: PRINCIPAL_INVESTIGATOR
Faculty of medicine, Zagazig University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zagazig University, Faculty of Medicine
Zagazig, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3527/20-2-2017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.